HER2-directed antibody–drug conjugate composed of trastuzumab linked to the microtubule inhibitor DM1; after HER2 binding and internalization, DM1 is released to disrupt microtubules in HER2-positive cells.
HER2-directed antibody-drug conjugate in which trastuzumab binds HER2 on tumor cells and is internalized; intracellular processing releases the maytansinoid payload DM1, which inhibits microtubule assembly leading to mitotic arrest and apoptosis. The trastuzumab component also blocks HER2 signaling and can mediate ADCC.
YES
DIRECT
Trastuzumab binds HER2 and is internalized; intracellular release of the DM1 payload inhibits microtubules, causing mitotic arrest and apoptosis. The Fc can also mediate ADCC.
HER2-directed antibody–drug conjugate composed of trastuzumab linked to the microtubule inhibitor DM1; after HER2 binding and internalization, DM1 is released to disrupt microtubules in HER2-positive cells.
HER2-directed antibody-drug conjugate in which trastuzumab binds HER2 on tumor cells and is internalized; intracellular processing releases the maytansinoid payload DM1, which inhibits microtubule assembly leading to mitotic arrest and apoptosis. The trastuzumab component also blocks HER2 signaling and can mediate ADCC.
NO
INDIRECT
T-DM1 targets HER2 on the cell surface; after internalization, the DM1 payload binds beta-tubulin to disrupt microtubules and induce mitotic arrest/apoptosis. Cells expressing beta-tubulin alone are not targeted—killing requires HER2-mediated delivery.
Chimeric anti-CD20 monoclonal antibody that depletes B cells via ADCC, complement activation, and apoptosis.
Chimeric anti-CD20 monoclonal IgG1 that binds CD20 on B cells and depletes CD20-positive cells via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and induction of apoptosis.
YES
DIRECT
Rituximab binds CD20 on B cells and induces killing via Fc-mediated ADCC by NK cells/macrophages, complement-dependent cytotoxicity, and apoptosis signaling.
Anti-CD22 antibody–drug conjugate that delivers calicheamicin to CD22-positive B cells, causing DNA double-strand breaks.
Humanized anti-CD22 antibody-drug conjugate that binds CD22 on B cells, is internalized, and releases the calicheamicin payload intracellularly; calicheamicin binds the DNA minor groove and induces double-strand breaks, triggering apoptosis.
YES
DIRECT
Anti-CD22 ADC binds CD22, is internalized, and releases calicheamicin intracellularly; the payload binds DNA’s minor groove, causes double‑strand breaks, and triggers apoptosis.
Anti-CD22 antibody–drug conjugate that delivers calicheamicin to CD22-positive B cells, causing DNA double-strand breaks.
Humanized anti-CD22 antibody-drug conjugate that binds CD22 on B cells, is internalized, and releases the calicheamicin payload intracellularly; calicheamicin binds the DNA minor groove and induces double-strand breaks, triggering apoptosis.
NO
INDIRECT
Inotuzumab ozogamicin binds CD22 on B cells, is internalized, and releases calicheamicin, which binds the DNA minor groove to cause double‑strand breaks and apoptosis. The DNA minor groove is the intracellular payload target, not the selective antigen determining which cells are killed.